Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hoffmann-LaRoche

Executive Summary

Patrick Zenner, Roche Labs senior VP-pharmaceuticals, is moving to corporate headquarters in Basel on two-year assignment as director of project management and drug regulatory affairs. Zenner, who was also a member of the Roche executive committee and board, will assume his new position Jan. 1, 1989. He will remain at the parent company for two years, to "facilitate and enhance cooperation and collaboration between Basel and Nutley (N.J.) in the critical areas related to international development and registration of pharmaceutical products," according to a Roche announcement of the move.

You may also be interested in...



Rare Disease Advocates Lobby US Congress For FDA Center of Excellence

Number one ask is for congressional pressure to centralize rare disease expertise at the agency, but advocates also are preparing legislation that would mandate the new center.

FDA’s 2021 Budget Priorities For Cosmetics, Food Programs Include AI Use In Postmarket Oversight

FDA’s food, dietary supplement and cosmetics division seeks funding to support its artificial intelligence capabilities, including post-market surveillance and speedy interventions in instances where safety issues arise. Also of note, the agency cites UV filters’ effects on the skin microbiome as a research priority in its fiscal 2021 budget justification to Congress.

Don't Take For Granted A Patient's Role In Clinical Trials, Experts Say

Catering to patients can help make clinical trials more accessible and useful, presenters argued at a recent conference.

UsernamePublicRestriction

Register

PS014267

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel